eGenesis is advancing genetically engineered porcine organs for human transplant. The company’s lead product (EGEN-2784) is for the treatment of patients with kidney failure. eGenesis has published the most extensive preclinical dataset in the field of cross-species transplantation, demonstrating consistent and durable long-term survival. In March 2024, the company’s lead product was used in the world’s first porcine kidney transplant in a living human patient. eGenesis is also advancing additional programs for patients with heart failure, liver failure.
industries
Advancing Human Health
Biology Biochemistry
Milestones
Lux investment: 2024
Founders
George Church
Luhan Yang
Lux partners
Peter Hébert